Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
The expression “immunogenic cell death” (ICD) refers to a functionally unique form of cell death that facilitates (instead of suppressing) a T cell-dependent immune response specific for dead cell-derived antigens. ICD critically relies on the activation of adaptive responses in dying cells, culmina...
Main Authors: | Abhishek D. Garg, Sanket More, Nicole Rufo, Odeta Mece, Maria Livia Sassano, Patrizia Agostinis, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-12-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1386829 |
Similar Items
-
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
by: Isaure Vanmeerbeek, et al.
Published: (2020-01-01) -
Trial watch: Dendritic cell-based anticancer immunotherapy
by: Abhishek D. Garg, et al.
Published: (2017-07-01) -
Trial watch: dendritic cell vaccination for cancer immunotherapy
by: Jenny Sprooten, et al.
Published: (2019-11-01) -
Trial watch: IDO inhibitors in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01) -
Trial watch: TLR3 agonists in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01)